Zimmer Biomet Holdings, Inc. (ZBH) Revenue by Segment

Executive TeamFinancialsSegments
Shareholders

Zimmer Biomet revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Zimmer Biomet's largest product or service was Knees, with $828.90 million or 38% of revenue, up 0.4% from a year earlier. Next: SET (27%), Hips (26%) and Technology and Data, Bone Cement and Surgical (9%).

By region, Americas brought in 62%, EMEA brought in 22% and Asia Pacific brought in 16% of revenue in Q2 fiscal 2026.

The fastest-growing product or service from a year earlier was Technology and Data, Bone Cement and Surgical (+21.1%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

ZBH logo

Zimmer Biomet Holdings, Inc.

ZBHUnited States
Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Zimmer Biomet revenue by product or service, last 4 quarters

Product or serviceQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
Knees$828.9M$828.6M$792.4M$826.0M38%
SET$586.0M$562.2M$541.5M$550.6M27%
Hips$562.7M$524.1M$506.2M$536.1M26%
Technology and Data, Bone Cement and Surgical$199.4M$171.8M$161.3M$164.6M9%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Zimmer Biomet revenue by region, last 4 quarters

RegionQ2 FY26Q1 FY26Q3 FY25Q2 FY25Share
Americas$1.4B$1.3B$1.3B$1.3B62%
EMEA$478.5M$489.9M$417.0M$458.1M22%
Asia Pacific$339.5M$272.3M$330.9M$332.2M16%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

Which product or service makes the most money for Zimmer Biomet?

Knees: $828.90 million, or 38% of revenue, in Q2 fiscal 2026.

What are Zimmer Biomet's main products and services?

By revenue in Q2 fiscal 2026: Knees (38%), SET (27%), Hips (26%) and Technology and Data, Bone Cement and Surgical (9%).

Where does Zimmer Biomet make its money?

By region in Q2 fiscal 2026: Americas (62%), EMEA (22%) and Asia Pacific (16%).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube